Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Companies in the Octagon Capital Advisors portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 10.9 | $31M | 548k | 57.20 | ||
| I Mab Sponsored Ads (IMAB) | 7.4 | $21M | 455k | 47.15 | ||
| Celldex Therapeutics Com New (CLDX) | 6.3 | $18M | 1.0M | 17.52 | ||
| Curis Com New (CRIS) | 6.2 | $18M | 2.2M | 8.19 | ||
| 4d Molecular Therapeutics In (FDMT) | 5.4 | $16M | 378k | 41.45 | ||
| Pmv Pharmaceuticals (PMVP) | 5.3 | $15M | 250k | 61.51 | ||
| Arvinas Ord (ARVN) | 5.3 | $15M | 179k | 84.93 | ||
| Gossamer Bio (GOSS) | 5.2 | $15M | 1.6M | 9.67 | ||
| Acceleron Pharma (XLRN) | 5.0 | $14M | 112k | 127.94 | ||
| Chemocentryx (CCXI) | 4.8 | $14M | 225k | 61.92 | ||
| Cardiff Oncology (CRDF) | 4.1 | $12M | 650k | 17.99 | ||
| Avidity Biosciences Ord (RNA) | 3.8 | $11M | 430k | 25.52 | ||
| Dyne Therapeutics (DYN) | 3.5 | $10M | 482k | 21.00 | ||
| Taysha Gene Therapies Com Shs (TSHA) | 2.9 | $8.5M | 320k | 26.54 | ||
Setup an alertOctagon Capital Advisors will file the next quarterly 13-HR in about 1 months. Would you like to be notified? |
||||||
| Arcus Biosciences Incorporated (RCUS) | 2.7 | $7.8M | 300k | 25.96 | ||
| Calliditas Therapeutics Ab Sponsered Ads (CALT) | 2.3 | $6.7M | 200k | 33.62 | ||
| Fibrogen (FGEN) | 1.9 | $5.4M | 146k | 37.09 | ||
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 1.8 | $5.2M | 295k | 17.67 | ||
| Revolution Medicines (RVMD) | 1.7 | $5.0M | 126k | 39.59 | ||
| Kura Oncology (KURA) | 1.7 | $4.9M | 150k | 32.66 | ||
| Iveric Bio (ISEE) | 1.6 | $4.7M | 680k | 6.91 | ||
| Helix Acquisition Corp Com Cl A (HLXA) | 1.6 | $4.5M | 400k | 11.37 | ||
| Kronos Bio (KRON) | 1.5 | $4.4M | 146k | 29.87 | ||
| Jiya Acquisition Corp Com Cl A (JYAC) | 1.1 | $3.1M | 300k | 10.30 | ||
| Viela Bio | 1.1 | $3.1M | 85k | 35.97 | ||
| Inventiva Sa Ads (IVA) | 1.0 | $2.9M | 200k | 14.50 | ||
| Arcutis Biotherapeutics (ARQT) | 1.0 | $2.8M | 100k | 28.13 | ||
| Ngm Biopharmaceuticals (NGM) | 0.8 | $2.3M | 75k | 30.30 | ||
| Aclaris Therapeutics (ACRS) | 0.8 | $2.3M | 350k | 6.47 | ||
| Kadmon Hldgs (KDMN) | 0.6 | $1.8M | 434k | 4.15 | ||
| Axsome Therapeutics (AXSM) | 0.6 | $1.6M | 20k | 81.45 | ||
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2020 Q4 filed Feb. 16, 2021